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SUMMARY
Background: Erectile dysfunction is a preoccupying 
issue, just like motor and bladder disability, in spinal 
cord injured (SCI) patients. This is particularly so be-
cause of the increasing prevalence of paraplegic and 
tetraplegic subjects and the fact that these patients are 
younger, and sexually active.
Objective: To determine the effects of Sildenafil (Via-
gra®) on erectile dysfunction in SCI patients.
Methods: After medical ethics committee approval 
and informed patient consent, we conducted a prospec-
tive inquiry between January and March 2007 in 16 
SCI patients who were under Sildenafil treatment for 
erectile dysfunction. An abridged version of the Inter-
national Index of Erectile Function (IIEF-5) question-
naire was completed the patients. 
Results: The mean age (range) of the patients was 
32.75 yrs (21-53 yrs). The mean duration of their dis-
ability was 47.75 months (4 yr). Trauma was the etiol-
ogy in 87.5% of the cases (44% were road accidents). 
12/16 patients were paraplegics (10 above T10) and 4 
were tetraplegics (1 above C4 and 3 below C5). The 
mean duration of sildenafil treatment was 18.75 
months (17 days-7 yr). 70% of the patients were satis-
fied with their erection after treatment. However, 10/16 
patients had concomitant treatment with alprostadil.
Conclusion: Sildenafil is a vasoactive drug which can 
be used as a simple, discrete and effective treatment for 
erectile dysfunction in SCI patients. This approach is 
compatible with the efforts to improve the quality of 
life and rehabilitation of these patients.
Keywords: paraplegia, spinal cord injury, erectile dys-
function, Sildenafil
INTRODUCTION
Care of spinal cord injured (SCI) patients is a major 
preoccupation regarding sexuality, motor and bladder 
dysfunctions. This is particularly so because of the 
increasing prevalence of paraplegic and tetraplegic 
subjects and the fact that these patients are younger, 
and sexually active. This increase in prevalence is di-
rectly related with the increase in life expectancy of 
these patients irrespective of the etiology. In fact, an 
inquiry conducted in France, in 2002, showed an inci-
dence of 19.4/million inhabitants and a prevalence of 
100-400/million regarding post trauma paraplegic and 
tetraplegic subjects.1
Erectile and ejaculation disorders in these patients re-
quire effective management in order to improve their 
social and familial rehabilitation. This preoccupation, 
shared by many research and healthcare teams has led, 
in the past years, to the use of vasoactive drugs like 
Sildenafil in view of improving the sexuality of pa-
tients with erectile dysfunction.2, 3 The objective of this 
study was to determine the effects of Sildenafil on 
erectile dysfunction in SCI patients.
MATERIALS AND METHODS
The study was approved by the ethics committee of the 
University of Bordeaux. Informed patient consent was 
obtained prior to data collection. From January to 
March 2007, we conducted an inquiry in 16 SCI para-
plegic and tetraplegic male patients who were either 
currently or previously admitted (2000-2007) at the 
Tour de Gassies Rehabilitation Center of Bor-
deaux/France. The inclusion criteria were male SCI 
patients who had been or currently treated by Sildenafil
for erectile dysfunction. None SCI patients and those 
incapable of completing the questionnaire were ex-
cluded. 
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A questionnaire based on the concise version of the 
International Index of Erectile Function (IIEF-5) 4 was 
sent by ordinary mail to some patients while others 
received the questionnaire on site. This 5-item ques-
tionnaire has been validated by the National Institutes 
of Health Consensus Panel. Additionally we assessed 
patient satisfaction. The data was analyzed using the 
EPI info 2000 software. The results were expressed as 
mean and standard results were expressed as mean and 
standard deviation or range.
RESULTS
The mean age (range) of the patients was 32.75 yrs 
(21-53 yrs). The mean duration of their disability was 
47.75 months (4 yr). Trauma was the etiology in 87.5% 
of the cases (44% were road accidents). 12/16 patients 
were paraplegics (10 above T10) and 4 were tetraple-
gics (1 above C4 and 3 below C5). The mean duration 
of sildenafil treatment was 18.75 months (17 days-7 
yr). 70% of the patients were satisfied with their erec-
tion after treatment. However, 10/16 patients had con-
comitant treatment with alprostadil.
Table 1 Clinical characteristics of the study population 
(N=16)





< 12 months 5 31.25
1-5 yrs 6 37.50
The main characteristics of the study population are 
shown in Table 1. The prescription and distribution 
profiles of sildenafil are presented in Table 2. The main 
responses of the patients are shown in Table 3.







<1 month 4 25




General practitioner 2 12.5
DISCUSSION
This study shows that sildenafil is an effective treat-
ment of erectile dysfunction in SCI patients. The study 
population is comparable to other series including 
Tetrafigap,1  Hulting3 and Giuliano6 with regard to 
young age and the fact that trauma was the major cause 
of the spinal cord lesion.1, 7-9






Q1. How do you rate your con-
fidence that you could get and 
keep an erection?
Not sure at all 10 62.5
Not very sure 3 18.75
Quite sure 2 12.5
Sure enough 1 6.25
Q2. When you had erections 
with sexual stimulation, how 
often were your erections hard 
enough for penetration (intro-




Most times 3 18.75
Always 9 56.25
Q.3 during sexual intercourse, 
how often were you able to 
maintain your erection after 
you had penetrated (entered) 
your partner?
Never 2 12.25
A few times 8 50
Sometimes 3 18.75
Most times 2 12.25
Always 1 6.25
Q.4 During sexual intercourse, 
how difficult was it to maintain 
your erection to completion of 
intercourse?
No attempt 2 12.25
Extremely difficult 2 12.25
Slightly difficult 4 25
Not difficult 8 50
Q5. When you attempted sexual 
intercourse, how often was it 
satisfactory for you?
No attempt 2 12.25
Rare 1 6.25
Sometimes 2 12.25
Most times 2 12.25
Always 9 56.25
However the evolution period of the disorder was 
shorter than in Tetrafigap’s series. 
In this study, sildenafil was mainly prescribed by 
physiotherapists. These specialists are more concerned 
with the sexual disorders of SCI patients. 
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In fact, the French Society of Urology recommended 
this approach with the physiotherapist in the frontline.10
However, the important role of general practitioners 
could not be totally excluded. 
The response to the IIEF-5 questionnaire corroborate to 
previous studies of Giuliano and Hulting.3,6 We used 
the IIEF-5 questionnaire because it is an auto evalua-
tion form with a high degree of sensitivity and specific-
ity in detecting the efficacy of treatment. It is not spe-
cifically designed for SCI patients. It consists of 5-
intems derived from 15 of the complete version. This 
questionnaire takes into account four of the five areas 
of sexual function: erection, orgasm, sexual desire. 4
This concise version is simple and fast to use during 
consultation. The first item of the HEF-5 deals with the
pretreatment status while the four other questions in-
volve the post-treatment status of the patients.
We also added questions on global satisfaction so that 
the patients could compare their erectile conditions 
before and after sildenafil treatment. Despite the high 
satisfaction rate of our patients, 10/16 of them used 
other vasoactive drugs like alprostadil (edex). The 
main explanation for this was that sildenafil was not 
reimbursed by the French social welfare. The majority 
of the patients expressed their desire for the reim-
bursement of this drug in SCI patients. Patients who 
failed both the sildenafil and alprostadil were advised 
to consult our local multidisciplinary team of physio-
therapists, neurosurgeons and anesthesiologists in order 
to determine whether they were suitable candidates for 
implantable sacral nerve stimulators. However, we did 
not assess the outcome of these consultations.
The results of this study are strictly in the hospital do-
main and could not be extrapolated to all SCI patients. 
Additionally, the sample size is too small to deduce 
any pertinent conclusions. However, our study pro-
vides further insight to the efficacy of Sildenafil on 
erectile dysfunction of SCI patients in corroboration 
with other studies. 2
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